Mesoblast Limited: stock overview

MESONASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$10.89

November 20, 2026Market cap $1.4B

What Ploutos Investor adds for Mesoblast

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 11 fiscal years, from FY2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

In short

Mesoblast had revenue of $120M in the fiscal year to June 30, 2026 and a net loss of $58M. Revenue grew by 74.5% a year on average over the last 5 years. It pays no dividend.

From its SEC filings (latest fiscal year to June 30, 2026) and the price of November 20, 2026.

Its SEC filings
Market cap
$1.4B
130M shares
P/E
–
Revenue, fiscal year
$120M
+74.5% a year over 5 years
Net margin
-47.8%

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2024–FY2026 fiscal years

+351.4% a year over 2 years

  • FY2026Jun 30, 202620-F
    Revenue$120M
  • FY2025Jun 30, 202520-F
    Revenue$17M
  • FY2024Jun 30, 202420-F
    Revenue$5.9M

Fiscal years in figures

MESO's revenue, profit, cash flow and dividend with each year-end price, from FY2016 to FY2023, 8 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $1.4B
$1.4B
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 2.3
2.5
FCF yield 3-year median: -3.6%
–
Earnings yield 
–

Profitability

Gross margin 
86.1%
Operating margin 
-47.3%
Net margin 3-year median: -593.9%
-47.8%
ROIC 
-6.5%
ROIC, 5-year average 
-10.5%
ROE, fiscal year 
-10.1%

Growth

Revenue, yearly change 
+599.2%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+74.5%

The yearly change compares FY2026 with FY2025.

Balance sheet

Cash 
$103M
Total debt 
–
Net cash 
–
Net debt / EBITDA 
–
Interest cover 
-2.4x
Current ratio 
–

Balance sheet of June 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+1.3%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
MESOBLAST LTD
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
June 30
Latest annual report
June 30, 2026
Reporting currency
USD
Shares
130M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Mesoblast's filings show?

These are Mesoblast's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MESO

Didn't find what you were looking for?

Ask us
What is MESO's market cap?

Mesoblast Limited's market cap is $1.4B, at a price of $10.89 on November 20, 2026 and 130M shares.

How much revenue does MESO have?

Mesoblast had revenue of $120M in the fiscal year to June 30, 2026. Over the last 5 years it changed by +74.5% a year on average.

Does MESO pay a dividend?

No. Mesoblast paid no regular dividend over the last 12 months.

Where do the figures come from?

From Mesoblast Limited's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.